Ocular Genomics Institute

The Ocular Genomics Institute (OGI) aims to translate genomic medicine into precision ophthalmic care for patients with inherited eye disorders. OGI researchers are working to achieve this goal through a combination of efforts, including: -Laboratory-based translational research on functional genetics, genomics, IPS-derived models of disease and genome editing. -The application of modern gene therapy technologies to identify new disease genes and improve inherited retinal disorder diagnosis -Clinical research directed toward the development of clinical trials of novel gene therapies and participation by our patients and clinicians in a number of gene therapy trials including the first in human study of in vivo CRISPR-Cas9 gene editing. -Providing state-of-the-art clinical care for patients with ophthalmic genetic disorders, including comprehensive genetic testing. -Providing DNA extraction and storage as part of the OGI BioBank for researchers to store samples long term for future genomics studies. The OGI multidisciplinary team works with several other departments and teams to achieve its mission. Via the Genomics Core, the OGI provides clinical genetic diagnostic testing and research services, including whole exome and whole genome sequencing,and copy number variant analyses, to both internal and external institutions.

网站

https://oculargenomics.meei.harvard.edu/

Ocular Genomics Institute的外部链接

所属行业

研究服务

规模

51-200 人

总部

Boston，Massachusetts

领域

Inherited retinal disorders、genomics和clinical trials